Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
In trial reports, Motus (oral) delivered about 10.4 percent average weight loss in human clinical trials over six months, with a high proportion of the loss from fat instead of lean mass
Regular check-ins help us track your progress, adjust your dosage as necessary, and make sure youre achieving your weight and body composition goals
Inconsistent dosing or skipping weekly injections ,ay reduce the medications effectiveness
The SUPRPASS-4 trial (262), involving 2002 participants with high-risk cardiovascular profiles followed for up to 104 weeks, showed no difference in 4-MACE events (cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina) with tirzepatide compared to insulin glargine (HR 0.74
US$ 24.08
US$ 24.13
US$ 27.63
US$ 23.72
US$ 27.26
US$ 25.92
US$ 27.74
US$ 21.60
US$ 28.69
